Citation: Liping Dong, Jinsong Ding, Lemei Zhu, Yujun Liu, Xiang Gao, Wenhu Zhou. Copper carbonate nanoparticles as an effective biomineralized carrier to load macromolecular drugs for multimodal therapy[J]. Chinese Chemical Letters, ;2023, 34(9): 108192. doi: 10.1016/j.cclet.2023.108192 shu

Copper carbonate nanoparticles as an effective biomineralized carrier to load macromolecular drugs for multimodal therapy

    * Corresponding authors.
    E-mail addresses: gaoxiang609@163.com (X. Gao), zhouwenhuyaoji@163.com (W. Zhou).
  • Received Date: 20 October 2022
    Revised Date: 1 February 2023
    Accepted Date: 3 February 2023
    Available Online: 5 February 2023

Figures(4)

  • Macromolecular drugs have attracted great interest as biotherapy to cure previously untreatable diseases. For clinical translation, biomacromolecules encounter several common druggability difficulties, such as in vivo instability and poor penetration to cross physiologic barriers, thus requiring sophisticated systems for drug delivery. Inspired by the natural biomineralization via interaction between inorganic ions and biomacromolecules, herein we rationally screened biocompatible transition metals to biomineralize with carbonate for macromolecules loading. Among the metal ions, Cu2+ was found to be the best candidate, and its superiority over the widely studied Ca2+ minerals was also demonstrated. Capitalized on this finding, copper carbonate nanoparticles were prepared via a simple mixing process to co-load glucose oxidase (GOx) and a HIF-α DNAzyme (DZ), achieving ultra-high loading capacity of 61%. Upon encapsulation into nanoparticles, enzymatic activity of both drugs was passivated to avoid potential side-effects during circulation, while the drugs could be rapidly released within 1 h in response to acidic pH to fully recover their activities. The nanoparticles could accumulate into tumor via intravenous injection, facilitate the cell membrane penetration, and release the payloads of GOx, DZ and Cu2+ inside cells to exert a series of anti-tumor effects. GOx caused tumor starvation by catalytic glucose consumption, and the concomitantly generated H2O2 byproduct boosted the Cu2+-mediated chemodynamic therapy (CDT). Meanwhile, the DZ silenced HIF-α expression to sensitize both starvation therapy and CDT. As a result, a synergistic tumor growth inhibition was achieved. This work provides a simple method to prepare biomineralized nanoparticles, and offers a general approach for macromolecular drugs delivery via Cu2+-based biomineralization.
  • Organic solar cells (OSCs) are a type of photovoltaic cells that use the organic conjugated materials as the photoactive materials. They show huge potential for commercial applications owing to the advantages of abundant raw materials, high flexibility, semitransparency, compatibility with low-cost large-area printing [1-11]. Thanks to the development of the photoactive materials (especially the Y-series acceptors), morphological control strategies, interlayer and device engineering, the power conversation efficiencies (PCEs) of OSCs have surpassed 19% [12-15]. However, the toxic halogenated solvents such as chloroform (CF), chlorobenzene (CB), and 1,2-dichlorobenzene (o-DCB) are always the best candidates for photoactive layer processing during the laboratory production of state-of-the-art OSCs devices. These toxic solvents pose serious threats to human health and the environment, constituting one of the major challenges in scaling up production of OSCs for industrial applications [16,17].

    The use of non-halogenated solvents eliminates potential health and safety concerns associated with the use of halogenated solvents, making the fabrication process safer for workers and the environment [18-20]. Nevertheless, the poor solubility of present photoactive materials in non-halogenated solvents leads to suboptimal morphologies, thereby significantly impacting their performance [21,22]. To address this issue, numerous molecular design strategies and processing techniques have been proposed by researchers to enhance the compatibility between photoactive materials and non-halogenated solvents. For example, Dong et al. synthesized an efficient acceptor, known as DTY6, with longer alkyl chains (2-decyltetradecyl) compared to Y6 [23]. The PM6:DTY6 devices showed an obvious improvement of PCE (16.1%) compared to the PM6:Y6 counterparts (10.8%) when processing in o-xylene (o-XY), owing to the restricted aggregation and reasonable domain size of DTY6 in the blends [23]. In addition, Song et al. used a mixed halogen-free solvent of carbon disulfide (CS2) and o-XY with the volume ratio of 7:3 to fabricated PM6:Y6-based OSC devices [24]. This approach yielded a high PCE of 16.5%, surpassing its counterparts processed with neat o-XY (13.3%). This is due to the mixed solvent that effectively increases the solubility and miscibility of PM6 and Y6, resulting in the optimal phase separation and proper aggregation domains within the active layer. Furthermore, a recent study by Daniel et al. developed a set of terpene-based binary solvent systems according to the Hansen solubility parameters (HSP), which were found to be both effective and environmentally friendly for a range of organic electronics devices [25]. Despite of the success achieved, the processing of bulk-heterojunction OSCs using non-halogen solvents remains a complicated and demanding task. Since the material nature of the polymer donors and the small molecule acceptors are distinct [26,27], the selection of non-halogenated solvents for processing should take a comprehensive consideration of the effects of material solubility and solvent volatility on the aggregation state and phase separation [23,24,28].

    Double-cable conjugated polymers [29-35] are a type of polymers where the acceptor units are covalently bonded to the donor main chain, commonly utilized in the fabrication of single-component organic solar cells (SCOSCs), leading to a simpler and more cost-effective manufacturing process. Recently, our group took the lead in synthesizing double-cable conjugated polymers with non-fused near-infrared (NIR) acceptors for use in SCOSCs, which delivered a high PCE of 10.09% [36]. Nevertheless, the new double-cable polymers named as DCPIC-EH can only dissolved in hot o-dichlorobenzene (o-DCB) solvent to prepare high-performance SCOSC devices. In this work, we designed a new double-cable polymer (DCPIC-BO) with long-branched alkyl chains (2-buthyloctyl, BO) on the TPDIC (1,3-bis(4,4-bis(2-buthyloctyl)-4H-cyclopenta[1,2-b:5,4-b’]dithiophen-2-yl)-5-(2-octyl)-4H-thieno[3,4-c]pyrrole-4,6(5H)‑dione) acceptor side units (Fig. 1a). The solubility of DCPIC-BO was substantially improved in both the halogen and non-halogen solvents, compared with DCPIC-EH. As a result, the DCPIC-BO-based devices processed using either halogen or non-halogen solvents (CB, o-XY, and THF) at a mild temperature of 40 ℃ demonstrate similar PCEs of ~9.7%. In stark contrast, DCPIC-EH exhibits poor solubility in o-XY and THF at low temperature, impeding its processing with non-halogen solvents. In addition, we found that 2-methylanisole (2-MA) and a mixed solvent of eucalyptol (Eu) and tetralin (Tet) also can be utilized as alternative non-halogen processing solvents for DCPIC-BO to fabricate highly efficient SCOSCs devices. Furthermore, we employed a solid additive (SAD) to prepare "absolutely halogen-free" SCOSCs devices. This approach enabled high PCEs exceeding 10% for small-area (0.04 cm2) devices and nearly 9% for devices with an area of 1 cm2.

    Figure 1

    Figure 1.  Chemical structures, absorption spectra and energy level diagram of DCPIC-EH and DCPIC-BO. (a) Schematic diagram showing the designed double-cable conjugated polymer DCPCI-BO from DCPIC-EH via side chain engineering. (b) Optical absorption spectra in o-XY solution and corresponding thin films. (c) Energy level diagram.

    As shown in Fig. 1a, the new double-cable polymer DCPIC-BO was synthesized by extending the alkyl chain on TPDIC acceptor side unit of DCPIC-EH that was previously reported [36] from 2-ethylhexyl (EH) to 2-butyloctyl (BO) (The detailed synthesis and characterizations can be found in Supporting information). The gel permeation chromatography measurement shows that the number-average molecular weight (Mn) of DCPIC-BO is 34.8 kDa (Fig. S1 in Supporting information), which is lower than that of DCPIC-EH (93.1 kDa) [36]. Despite our attempts to synthesize several batches of DCPIC-BO, we were unable to achieve a high Mn comparable to that of DCPIC-EH. This has puzzled us for a considerable period, and we intend to investigate the underlying reasons in more detail.

    The ultraviolet-visible (UV–vis) absorption spectra of the DCPIC-EH and DCPIC-BO in dilute o-XY (a widely used non-halogen solvent with moderate boiling point and excellent dissolving ability) solutions and thin films are shown in Fig. 1b. The absorption spectrum of DCPIC-BO in solution shows obvious blue shift (~37 nm) compared with that of DCPIC-EH, revealing the decrease in aggregation of DCPIC-BO in o-XY. The absorption spectra of DCPIC-BO in CB and THF are also presented in Fig. S2a (Supporting information), which further verify the enhanced solubility of DCPIC-BO in non-halogen solvents. When converted from the solution state to the thin films, the absorption profiles of the two polymers exhibit similar trends within the 400–900 nm range with the absorbance edge of DCPIC-BO slightly blue-shifted by ~9 nm relative to that of DCPIC-EH, which can be attributed to the steric hindrance effect of a long-branched alkyl chain in DCPIC-BO that results in the increase of laminar spacing. Despite of the slight blue shift, the DCPIC-BO film shows a superior aggregation, which is indicated by an increased ratio between the 0–0/0–1 peaks and due to the superior solubility of DCPIC-BO in o-XY that contributes to a favorable morphology. Further, the effect of alkyl chain on the frontier energy levels of the two polymers were determined by cyclic voltammogram (CV) measurements, as shown in Fig. S3 (Supporting information) and Fig. 1c. Specifically, DCPIC-BO and DCPIC-EH display identical highest occupied molecular orbital (HOMO) energy levels of −5.56 eV, while the lowest unoccupied molecular orbital (LUMO) energy level of DCPIC-BO (−3.72 eV) is slightly up-shifted from that of DCPIC-EH (−3.75 eV), which is considered to help in achieving a higher open-circuit voltage (Voc) when manufacturing SCOSC devices.

    Then, the solubility of DCPCI-EH and DCPIC-BO in various commonly used solvents for processing organic solar cells was investigated, including halogenated and non-halogenated solvents, such as o-DCB, CB, o-XY and THF. The chemical structures of these solvents are illustrated in Fig. 2a. Fig. S4 shows pictures of the two polymers dissolved in different solvents (10 mg/mL, the lowest concentration for proper photoactive layer thickness) and the corresponding thin films. It can be found that DCPIC-EH exhibits exiguous solubility (<1 mg/mL) in o-XY and THF at moderate temperatures (40 ℃), resulting in severe aggregation and poor film quality. Following continuous heating of the solution on a hot stage, the solubility of DCPIC-EH in o-DCB and o-XY was enhanced, while remaining slightly soluble in THF. As anticipated, the long alkyl side chains in DCPIC-BO contribute to its excellent solubility in CB, o-XY, and THF, at both moderate and high temperatures, thereby enabling its solution processing into uniform and flat films.

    Figure 2

    Figure 2.  (a) Molecule structures of CB, o-DCB and o-XY, THF solvents. (b) Scheme of devices configuration. J-V curves of (c) DCPIC-EH and (d) DCPIC-BO-based devices processed with various solvents. (e, f) The corresponding EQE plots.

    To check the photovoltaic performance of the DCPIC-EH and DCPIC-BO processed from the above solutions, the SCOSCs devices with an inverted configuration of glass/ITO/ZnO/active layer/MoO3/Ag were fabricated, as depicted in Fig. 2b. 1,8-Diiodooctane (DIO) was used to optimize the morphology of polymer films. Firstly, the optimal temperature to prepare the polymer solutions with different solvents were investigated. As shown in Figs. S5a and b and Table S1 (Supporting information), for DCPIC-EH-based devices, the optimal performance was obtained by the o-DCB solution with a temperature of 100 ℃, showing an impressive PCE of 10.03%, a Voc of 0.775 V, a short-circuit current density (Jsc) of 20.55 mA/cm2 and a fill factor (FF) of 63.04%, while devices processed from o-XY solution under 100 ℃ yielded a decreased PCE of 9.36%. Notably, it was observed that when the temperature of the polymer solutions of o-DCB and o-XY is at 70 ℃, the PCEs are significantly reduced to 8.84% and 2.30%, respectively. Furthermore, the low solubility of DCPIC-EH in o-XY (40 ℃) and in THF at either 40 ℃ or 60 ℃ makes it difficult to obtain working devices. However, when replacing DCPIC-EH by DCPIC-BO, the solvent and temperature dependence is significantly reduced. As shown in Figs. S5c and e and Table S2 (Supporting information), regardless of whether the processing solvent is CB or o-XY and whether the solution temperature is 40 ℃ or 100 ℃, the resulting devices exhibit closed PCE values around 9.7%. Even processed from THF, a PCE of 9.76% can be achieved at solution temperature of 60 ℃ and only slightly decreases to 8.32% at 40 ℃. The current density-voltage (J-V) curves and external quantum efficiency (EQE) spectra for the best devices processed from different solvents are shown in Figs. 2c-f and the corresponding photovoltaic parameters are summarized in Table 1. The higher Vocs exhibited by the DCPIC-BO-based devices compared with those based on DCPIC-EH can be attributed to the reduction in non-radiative charge carrier decay resulting from the increased donor-acceptor spacing facilitated by the long-branched alkyl chain in DCPIC-BO [37]. All the above results indicate that the long-branched alkyl chain enhance the solubility of DCPIC-BO in different solvents, either halogenated or non-halogenated solvents, enabling the solution processing at both moderate and high temperatures to achieve high photovoltaic performance.

    Table 1

    Table 1.  Photovoltaic parameters of the devices processed from different solvents.
    DownLoad: CSV

    Further, atomic force microscopy (AFM) was carried out to detect the surface morphologies and phase separation of DCPCI-BO films processed from CB, o-XY and THF. As shown in Fig. S6 (Supporting information), the surface roughness (RMS) of o-XY and THF processed DCPIC-BO films were 0.63 nm and 0.56 nm, respectively, which were comparable to that processed from CB solution. Moreover, the DCPIC-BO films processed from CB, o-XY and THF all exhibit delicate phase separation, which is consistent with the results of o-DCB processed DCPIC-EH in our previous reports [36]. Also, grazing incidence wide-angle X-ray scattering (GIWAXS) was applied to study the molecular packing and crystalline behaviors of the DCPIC-BO films. The 2D GIWAXS images of CB, o-XY and THF processed DCPIC-BO films and the corresponding 1D in-plane (IP) and out-of-plane (OOP) plots are shown in Fig. 3 and the crystalline parameters are summarized in Table S4 (Supporting information). It reveals that, compared with the film processed from CB, similar face-on orientation and crystallinity can be obtained by both o-XY and THF processed films, which was further verified by the pretty similar optical absorption spectra of films processed from CB, o-XY and THF solutions (Fig. S2b in Supporting information).

    Figure 3

    Figure 3.  2D GIWAXS images of (a) CB, (b) o-XY and (c) THF-processed DCPIC-BO films. (d) In-plane and (e) out of plane 1D plots of the corresponding GIWAXS images.

    Moreover, we investigated whether DCPIC-BO can be processed by other non-halogenated solvents. Surprisingly, solvents including 2-MA, Eu and Tet (Fig. 4a) also shows capability of solution processing of DCPIC-BO. Specifically, 2-MA-based devices exhibit an optimal PCE of 9.11% with a Voc of 0.805 V, a Jsc of 19.23 mA/cm2 and an FF of 58.80%, as well as obtaining an efficiency of 8.60% by using a mixed solvent recipe of Eu and Tet as reported in the literature (Table S3 in Supporting information, Fig. 4b) [25].

    Figure 4

    Figure 4.  (a) The molecular structure of 2-MA, Eu and Tet. (b) J-V curves of DCPIC-BO processed from 2-MA, Eu and Tet. (c) J-V curves of DCPIC-BO-based small-area (0.04 cm2) devices processed from o-XY with SAD solid additive. (d) J-V curves of DCPIC-BO-based devices with 1 cm2 area.

    Furthermore, to address the non-environmental friendliness of DIO, we substituted DIO with a non-halogen solid additive (SAD, inset of Fig. 4c) in o-XY to produce completely halogen-free DCPCI-BO-based devices [38]. The SAD-based small-area (0.04 cm2) devices exhibited a remarkable efficiency of 10.10% (Fig. 4c), and devices with an area of 1 cm2 achieved an efficiency of 9.12% (Fig. 4d). These results confirm that the double-cable conjugated polymer DCPIC-BO is an efficient organic photovoltaic material that can be processed using non-halogen solvents.

    In this work, we synthesized a double-cable conjugated polymer (DCPIC-BO) by extending the alkyl side chains of the acceptor side units in DCPIC-EH and utilized as the light-absorbing material in solution-processed SCOSCs. The results demonstrate that DCPIC-BO-based devices processed from either halogen or non-halogen solvents (CB, o-XY, and THF) at a mild temperature of 40 ℃ exhibit comparable PCEs of ~9.7%. In contrast, DCPIC-EH cannot be solution-processed in o-XY and THF at low temperatures. DCPI-EH is soluble in o-XY at 100 ℃, yet the efficiency of o-XY-processed devices (9.36%) is still lower than that of o-DCB (10.03%). AFM and GIWAXS analyses suggest that the DCPIC-BO treated with non-halogen solvents results in an ideal film morphology, similar to that obtained with halogen solvents. Moreover, DCPIC-BO can be treated with other non-halogen solvents, such as 2-MA, Eu, and Tet. Of particular significance is that o-XY-processed DCPIC-BO devices fabricated with a non-halogen solid additive (SAD) achieve a high PCE of 10.1%. This work not only presents a double-cable conjugated polymer with the advantages of non-halogen solvent processing, but also provides a straightforward approach to modify conjugated polymers for achieving environmentally friendly manufacturing.

    The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

    This study is jointly supported by Beijing Natural Science Foundation (Nos. JQ21006 and 2212045) and National Natural Science Foundation of China (NSFC, Nos. 52073016 and 92163128). This work was further supported by the Fundamental Research Funds for the Central Universities (Nos. buctrc202111, buctrc201828 and XK1802-2), and the Opening Foundation of State Key Laboratory of Organic-Inorganic Composites of Beijing University of Chemical Technology (No. oic-202201006).

    Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.cclet.2023.108527.


    1. [1]

      M. Rütter, N. Milošević, A. David, J. Control. Release 330 (2021) 1191–1207.  doi: 10.1016/j.jconrel.2020.11.026

    2. [2]

      P. Tyagi, J.L. Santos, Drug Discov. Today 23 (2018) 1053–1061.  doi: 10.1016/j.drudis.2018.01.017

    3. [3]

      L. Guo, S. Zhong, P. Liu, M. Guo, J. Ding, W. Zhou, Small 18 (2022) e2202604.  doi: 10.1002/smll.202202604

    4. [4]

      W. Sun, Y. Xu, Y. Yao, et al., J. Nanobiotechnol. 20 (2022) 88.  doi: 10.1186/s12951-022-01296-x

    5. [5]

      Q. Guo, C. Jiang, Acta Pharm. Sin. B 10 (2020) 979–986.  doi: 10.1016/j.apsb.2020.01.009

    6. [6]

      Y. Song, Y. Huang, F. Zhou, J. Ding, W. Zhou, Chin. Chem. Lett. 33 (2022) 597–612.  doi: 10.1016/j.cclet.2021.08.090

    7. [7]

      R. Liu, C. Luo, Z. Pang, et al., Chin. Chem. Lett. 34 (2023) 107518.  doi: 10.1016/j.cclet.2022.05.032

    8. [8]

      J. Deng, R. Wang, S. Huang, J. Ding, W. Zhou, Chin. Chem. Lett. 34(2023) 107588.  doi: 10.1016/j.cclet.2022.06.011

    9. [9]

      B. Hu, L. Zhong, Y. Weng, et al., Signal. Transduct. Target. Ther. 5 (2020) 101.  doi: 10.1038/s41392-020-0207-x

    10. [10]

      W. Wang, X. Liu, X. Zheng, H.J. Jin, X. Li, Adv. Healthc. Mater. 9 (2020) e2001117.  doi: 10.1002/adhm.202001117

    11. [11]

      S. Yao, B. Jin, Z. Liu, et al., Adv. Mater. 29 (2017) 1605903.  doi: 10.1002/adma.201605903

    12. [12]

      N.H.E. Khare, M.J. Buehler, Nat. Rev. Mater. 6 (2021) 421–436.  doi: 10.1038/s41578-020-00270-z

    13. [13]

      C. Xu, Y. Yan, J. Tan, et al., Adv. Funct. Mater. 29 (2019) 1808146.  doi: 10.1002/adfm.201808146

    14. [14]

      D.S. Maleki, S. Sharifi, E. Ahmadian, et al., Expert. Opin. Drug Deliv. 16 (2019) 331–345.  doi: 10.1080/17425247.2019.1587408

    15. [15]

      S.E. Wolf, L. Müller, R. Barrea, et al., Nanoscale 3 (2011) 1158–1165.  doi: 10.1039/c0nr00761g

    16. [16]

      W. Zhou, R. Saran, J. Liu, Chem. Rev. 117 (2017) 8272–8325.  doi: 10.1021/acs.chemrev.7b00063

    17. [17]

      X. Jing, F. Yang, C. Shao, et al., Mol. Cancer 18 (2019) 157.  doi: 10.1186/s12943-019-1089-9

    18. [18]

      L.H. Fu, C. Qi, J. Lin, P. Huang, Chem. Soc. Rev. 47 (2018) 6454–6472.  doi: 10.1039/C7CS00891K

    19. [19]

      Y. Zeng, H. Zhou, J. Ding, W. Zhou, Theranostics 11 (2021) 8270–8282.  doi: 10.7150/thno.60758

    20. [20]

      J.S. Cao, C. Chen, Y.H. Wang, et al., Oncol. Lett. 12 (2016) 2033–2037.  doi: 10.3892/ol.2016.4839

    21. [21]

      Z.H. Zhao, J. Yan, K. Ling, et al., Adv. Funct. Mater. 31 (2021) 2106471.  doi: 10.1002/adfm.202106471

    1. [1]

      M. Rütter, N. Milošević, A. David, J. Control. Release 330 (2021) 1191–1207.  doi: 10.1016/j.jconrel.2020.11.026

    2. [2]

      P. Tyagi, J.L. Santos, Drug Discov. Today 23 (2018) 1053–1061.  doi: 10.1016/j.drudis.2018.01.017

    3. [3]

      L. Guo, S. Zhong, P. Liu, M. Guo, J. Ding, W. Zhou, Small 18 (2022) e2202604.  doi: 10.1002/smll.202202604

    4. [4]

      W. Sun, Y. Xu, Y. Yao, et al., J. Nanobiotechnol. 20 (2022) 88.  doi: 10.1186/s12951-022-01296-x

    5. [5]

      Q. Guo, C. Jiang, Acta Pharm. Sin. B 10 (2020) 979–986.  doi: 10.1016/j.apsb.2020.01.009

    6. [6]

      Y. Song, Y. Huang, F. Zhou, J. Ding, W. Zhou, Chin. Chem. Lett. 33 (2022) 597–612.  doi: 10.1016/j.cclet.2021.08.090

    7. [7]

      R. Liu, C. Luo, Z. Pang, et al., Chin. Chem. Lett. 34 (2023) 107518.  doi: 10.1016/j.cclet.2022.05.032

    8. [8]

      J. Deng, R. Wang, S. Huang, J. Ding, W. Zhou, Chin. Chem. Lett. 34(2023) 107588.  doi: 10.1016/j.cclet.2022.06.011

    9. [9]

      B. Hu, L. Zhong, Y. Weng, et al., Signal. Transduct. Target. Ther. 5 (2020) 101.  doi: 10.1038/s41392-020-0207-x

    10. [10]

      W. Wang, X. Liu, X. Zheng, H.J. Jin, X. Li, Adv. Healthc. Mater. 9 (2020) e2001117.  doi: 10.1002/adhm.202001117

    11. [11]

      S. Yao, B. Jin, Z. Liu, et al., Adv. Mater. 29 (2017) 1605903.  doi: 10.1002/adma.201605903

    12. [12]

      N.H.E. Khare, M.J. Buehler, Nat. Rev. Mater. 6 (2021) 421–436.  doi: 10.1038/s41578-020-00270-z

    13. [13]

      C. Xu, Y. Yan, J. Tan, et al., Adv. Funct. Mater. 29 (2019) 1808146.  doi: 10.1002/adfm.201808146

    14. [14]

      D.S. Maleki, S. Sharifi, E. Ahmadian, et al., Expert. Opin. Drug Deliv. 16 (2019) 331–345.  doi: 10.1080/17425247.2019.1587408

    15. [15]

      S.E. Wolf, L. Müller, R. Barrea, et al., Nanoscale 3 (2011) 1158–1165.  doi: 10.1039/c0nr00761g

    16. [16]

      W. Zhou, R. Saran, J. Liu, Chem. Rev. 117 (2017) 8272–8325.  doi: 10.1021/acs.chemrev.7b00063

    17. [17]

      X. Jing, F. Yang, C. Shao, et al., Mol. Cancer 18 (2019) 157.  doi: 10.1186/s12943-019-1089-9

    18. [18]

      L.H. Fu, C. Qi, J. Lin, P. Huang, Chem. Soc. Rev. 47 (2018) 6454–6472.  doi: 10.1039/C7CS00891K

    19. [19]

      Y. Zeng, H. Zhou, J. Ding, W. Zhou, Theranostics 11 (2021) 8270–8282.  doi: 10.7150/thno.60758

    20. [20]

      J.S. Cao, C. Chen, Y.H. Wang, et al., Oncol. Lett. 12 (2016) 2033–2037.  doi: 10.3892/ol.2016.4839

    21. [21]

      Z.H. Zhao, J. Yan, K. Ling, et al., Adv. Funct. Mater. 31 (2021) 2106471.  doi: 10.1002/adfm.202106471

  • 加载中
    1. [1]

      Yang LiuMinglu LiJianxun DingXuesi Chen . Glycoengineering-assistant biomineralization for tumor blockade therapy. Chinese Chemical Letters, 2025, 36(5): 110146-. doi: 10.1016/j.cclet.2024.110146

    2. [2]

      Yuanzheng WangChen ZhangShuyan HanXiaoli KongChangyun QuanJun WuWei Zhang . Cancer cell membrane camouflaged biomimetic gelatin-based nanogel for tumor inhibition. Chinese Chemical Letters, 2024, 35(11): 109578-. doi: 10.1016/j.cclet.2024.109578

    3. [3]

      Jiaqi HuangRenjiang KongYanmei LiNi YanYeyang WuZiwen QiuZhenming LuXiaona RaoShiying LiHong Cheng . Feedback enhanced tumor targeting delivery of albumin-based nanomedicine to amplify photodynamic therapy by regulating AMPK signaling and inhibiting GSTs. Chinese Chemical Letters, 2024, 35(8): 109254-. doi: 10.1016/j.cclet.2023.109254

    4. [4]

      Weiqian JinLin LiaoTao QinXiaoxuan GuanHuyang GaoPeng LiangMing GaoJunyu Lu . Recent advances in nanomedicine therapy for bacterial pneumonia. Chinese Chemical Letters, 2025, 36(6): 110920-. doi: 10.1016/j.cclet.2025.110920

    5. [5]

      Hao ZhangHao LiuKe HuangQingxiu XiaHongjie XiongXiaohui LiuHui JiangXuemei Wang . Ionic exchange based intracellular self-assembly of pitaya-structured nanoparticles for tumor imaging. Chinese Chemical Letters, 2025, 36(6): 110281-. doi: 10.1016/j.cclet.2024.110281

    6. [6]

      Linghui ZouMeng ChengKaili HuJianfang FengLiangxing Tu . Vesicular drug delivery systems for oral absorption enhancement. Chinese Chemical Letters, 2024, 35(7): 109129-. doi: 10.1016/j.cclet.2023.109129

    7. [7]

      Zhe LiPing-Zhao LiangLi XuFei-Yu YangTian-Bing RenLin YuanXia YinXiao-Bing Zhang . Three positive charge nonapoptotic-induced photosensitizer with excellent water solubility for tumor therapy. Chinese Chemical Letters, 2024, 35(8): 109190-. doi: 10.1016/j.cclet.2023.109190

    8. [8]

      Liangliang JiaYe HongXinyu HeYing ZhouLiujiao RenHongjun DuBin ZhaoBin QinZhe YangDi Gao . Fighting hypoxia to improve photodynamic therapy-driven immunotherapy: Alleviating, exploiting and disregarding. Chinese Chemical Letters, 2025, 36(2): 109957-. doi: 10.1016/j.cclet.2024.109957

    9. [9]

      Zhongyu WangLijun WangHuaixin Zhao . DNA-based nanosystems to generate reactive oxygen species for nanomedicine. Chinese Chemical Letters, 2024, 35(11): 109637-. doi: 10.1016/j.cclet.2024.109637

    10. [10]

      Zhilong XieGuohui ZhangYa MengYefei TongJian DengHonghui LiQingqing MaShisong HanWenjun Ni . A natural nano-platform: Advances in drug delivery system with recombinant high-density lipoprotein. Chinese Chemical Letters, 2024, 35(11): 109584-. doi: 10.1016/j.cclet.2024.109584

    11. [11]

      Yating ZhengYulan HuangJing LuoXuqi PengXiran GuiGang LiuYang Zhang . Supercritical fluid technology: A game-changer for biomacromolecular nanomedicine preparation and biomedical application. Chinese Chemical Letters, 2024, 35(7): 109169-. doi: 10.1016/j.cclet.2023.109169

    12. [12]

      Keyang LiYanan WangYatao XuGuohua ShiSixian WeiXue ZhangBaomei ZhangQiang JiaHuanhua XuLiangmin YuJun WuZhiyu He . Flash nanocomplexation (FNC): A new microvolume mixing method for nanomedicine formulation. Chinese Chemical Letters, 2024, 35(10): 109511-. doi: 10.1016/j.cclet.2024.109511

    13. [13]

      Mengwei YeQingqing XuHuanhuan JianYiduo DingWenpeng ZhaoChenxiao WangJunya LuShuaipeng FengSiling WangQinfu Zhao . Recent trends of biodegradable mesoporous silica based nanoplatforms for enhanced tumor theranostics. Chinese Chemical Letters, 2025, 36(6): 110221-. doi: 10.1016/j.cclet.2024.110221

    14. [14]

      Han WuYumei WangZekai RenHailin CongYouqing ShenBing Yu . The nanocarrier strategy for crossing the blood-brain barrier in glioma therapy. Chinese Chemical Letters, 2025, 36(4): 109996-. doi: 10.1016/j.cclet.2024.109996

    15. [15]

      Xingqun PuRongrong LiuYuting XieChenjing YangJingyi ChenBaoling GuoChun-Xia ZhaoPeng ZhaoJian RuanFangfu YeDavid A WeitzDong Chen . One-step preparation of biocompatible amphiphilic dimer nanoparticles with tunable particle morphology and surface property for interface stabilization and drug delivery. Chinese Chemical Letters, 2025, 36(3): 109820-. doi: 10.1016/j.cclet.2024.109820

    16. [16]

      Chong LiuNanthi BolanAnushka Upamali RajapakshaHailong WangParamasivan BalasubramanianPengyan ZhangXuan Cuong NguyenFayong Li . Critical review of biochar for the removal of emerging inorganic pollutants from wastewater. Chinese Chemical Letters, 2025, 36(2): 109960-. doi: 10.1016/j.cclet.2024.109960

    17. [17]

      Makhloufi ZoulikhaZhongjian ChenJun WuWei He . Approved delivery strategies for biopharmaceuticals. Chinese Chemical Letters, 2025, 36(2): 110225-. doi: 10.1016/j.cclet.2024.110225

    18. [18]

      Jing ZhangCharles WangYaoyao ZhangHaining XiaYujuan WangKun MaJunfeng Wang . Application of magnetotactic bacteria as engineering microrobots: Higher delivery efficiency of antitumor medicine. Chinese Chemical Letters, 2024, 35(10): 109420-. doi: 10.1016/j.cclet.2023.109420

    19. [19]

      Tong TongLezong ChenSiying WuZhong CaoYuanbin SongJun Wu . Establishment of a leucine-based poly(ester amide)s library with self-anticancer effect as nano-drug carrier for colorectal cancer treatment. Chinese Chemical Letters, 2024, 35(12): 109689-. doi: 10.1016/j.cclet.2024.109689

    20. [20]

      Jiaxuan WangTonghe LiuBingxiang WangZiwei LiYuzhong NiuHou ChenYing Zhang . Synthesis of polyhydroxyl-capped PAMAM dendrimer/silica composites for the adsorption of aqueous Hg(II) and Ag(I). Chinese Chemical Letters, 2024, 35(12): 109900-. doi: 10.1016/j.cclet.2024.109900

Metrics
  • PDF Downloads(9)
  • Abstract views(643)
  • HTML views(16)

通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Address:Zhongguancun North First Street 2,100190 Beijing, PR China Tel: +86-010-82449177-888
Powered By info@rhhz.net

/

DownLoad:  Full-Size Img  PowerPoint
Return